Informace o publikaci

Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY

Autoři	CHATZIKONSTANTINOU Thomas SCARFO Lydia KARAKATSOULIS Georgios MINGA Eva CHAMOU Dimitra IACOBONI Gloria KOTAŠKOVÁ Jana DEMOSTHENOUS Christos SMOLEJ Lukas MULLIGAN Stephen ALCOCEBA Miguel AL-SHEMARI Salem AURRAN-SCHLEINITZ Thérese BACCHIARRI Francesca BELLIDO Mar BIJOU Fontanet CALLEJA Anne MEDINA Angeles KHAN Mehreen Ali CASSIN Ramona CHATZILEONTIADOU Sofia COLLADO Rosa CHRISTIAN Amy DAVIS Zadie DIMOU Maria DONALDSON David SANTOS Gimena Dos DRETA Barbara EFSTATHOPOULOU Maria EL-ASHWAH Shaimaa ENRICO Alicia FRESA Alberto GALIMBERTI Sara GALITZIA Andrea GARCÍA-SERRA Rocío GIMENO Eva GONZÁLEZ-GASCÓN-Y-MARÍN Isabel GOZZETTI Alessandro GUARENTE Valerio GUIEZE Romain GOGIA Ajay GUPTA Ritu HARROP Sean HATZIMICHAEL Eleftheria HERISHANU Yair JOSÉ-ÁNGEL Hernández-Rivas INCHIAPPA Luca JAKSIC Ozren JANSSEN Susanne KALICIŃSKA Elżbieta KAMEL Laribi KARAKUS Volkan KATER Arnon P KHO Bonnie KISLOVA Maria KONSTANTINOU Eliana KOREN-MICHOWITZ Maya KOTSIANIDIS Ioannis KREITMAN Robert J LABRADOR Jorge LAD Deepesh MARK-DAVID Levin LEVY Ilana LONGVAL Thomas LOPEZ-GARCIA Alberto MARQUET Juan MARTIN-RODRÍGUEZ Lucia MAYNADIÉ Marc MASLEJOVA Stanislava MAYOR-BASTIDA Carlota MIHALJEVIC Biljana MILOSEVIC Ivana MIRAS Fatima MOIA Riccardo MORAWSKA Marta MURRU Roberta NATH Uttam Kumar NAVARRO-BAILÓN Almudena OLIVEIRA Ana C OLIVIERI Jacopo OSCIER David PANOVSKA-STAVRIDIS Irina PAPAIOANNOU Maria PAPAJÍK Tomas KUBOVA Zuzana PHUMPHUKHIEO Punyarat PIERIE Cheyenne PUIGGROS Anna RANI Lata REDA Gianluigi RIGOLIN Gian Matteo RUCHLEMER Rosa SANTOS Marcos Daniel de Deus SCHIPANI Mattia SCHIWITZA Annett SHEN Yandong SIMKOVIC Martin SMIRNOVA Svetlana SOLIMAN Dina Sameh Abdelrahman SPACEK Martin TADMOR Tamar TOMIC Kristina TSE Eric VASSILAKOPOULOS Theodoros VISENTIN Andrea VITALE Candida TRESCKOW Julia von VRACHIOLIAS George VUKOVIC Vojin WALEWSKA Renata WASIK-SZCZEPANEK Ewa XU Zhenshu YAGCI Munci YANEZ Lucrecia YASSIN Mohamed ZUCHNICKA Jana ANGELOPOULOU Maria ANTIC Darko BIDERMAN Bella CATHERWOOD Mark CLAUS Rainer COSCIA Marta CUNEO Antonio DEMIRKAN Fatih ESPINET Blanca GAIDANO Gianluca KALASHNIKOVA Olga B LAURENTI Luca NIKITIN Eugene PANGALIS Gerassimos A PANAGIOTIDIS Panagiotis POPOV Viola Maria POSPISILOVA Sarka SPORTOLETTI Paolo STAVROYIANNI Niki TAM Constantine TRENTIN Livio CHATZIDIMITRIOU Anastasia BOSCH Francesc DOUBEK Michael GHIA Paolo STAMATOPOULOS Kostas
Rok publikování	2023
Druh	Článek v odborném periodiku
Časopis / Zdroj	EClinicalMedicine
Fakulta / Pracoviště MU	Lékařská fakulta
Citace
www	https://www.sciencedirect.com/science/article/pii/S2589537023004844?via%3Dihub
Doi	http://dx.doi.org/10.1016/j.eclinm.2023.102307
Klíčová slova	Chronic lymphocytic leukemia; Other malignancies; Other cancers; Second primary malignancies
Popis	Background Patients with chronic lymphocytic leukemia (CLL) have a higher risk of developing other malignancies (OMs) compared to the general population. However, the impact of CLL-related risk factors and CLL-directed treatment is still unclear and represents the focus of this work. Methods We conducted a retrospective international multicenter study to assess the incidence of OMs and detect potential risk factors in 19,705 patients with CLL, small lymphocytic lymphoma, or high-count CLL-like monoclonal B-cell lymphocytosis, diagnosed between 2000 and 2016. Data collection took place between October 2020 and March 2022. Findings In 129,254 years of follow-up after CLL diagnosis, 3513 OMs were diagnosed (27.2 OMs/1000 person-years). The most common hematological OMs were Richter transformation, myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Non-melanoma skin (NMSC) and prostate cancers were the most common solid tumors (STs). The only predictor for MDS and AML development was treatment with fludarabine and cyclophosphamide with/without rituximab (FC ± R) (OR = 3.7; 95% CI = 2.79–4.91; p < 0.001). STs were more frequent in males and patients with unmutated immunoglobulin heavy variable genes (OR = 1.77; 95% CI = 1.49–2.11; p < 0.001/OR = 1.89; 95% CI = 1.6–2.24; p < 0.001). CLL-directed treatment was associated with non-melanoma skin and prostate cancers (OR = 1.8; 95% CI = 1.36–2.41; p < 0.001/OR = 2.11; 95% CI = 1.12–3.97; p = 0.021). In contrast, breast cancers were more frequent in untreated patients (OR = 0.17; 95% CI = 0.08–0.33; p < 0.001). Patients with CLL and an OM had inferior overall survival (OS) than those without. AML and MDS conferred the worst OS (p < 0.001). Interpretation OMs in CLL impact on OS. Treatment for CLL increased the risk for AML/MDS, prostate cancer, and NMSC. FCR was associated with increased risk for AML/MDS.